公开(公告)号：US20220226494A1

公开(公告)日：2022-07-21

申请号：US17580134

申请日：2022-01-20

Applicant: AbbVie Inc.

Inventor： Erwin R. Boghaert ,  Milan Bruncko ,  Andrew C. Phillips ,  Andrew J. Souers ,  Kamel Izeradjene ,  John E. Harlan

IPC: A61K47/68 ,  C07K16/28 ,  A61P35/00

Abstract: The present disclosure relates to anti-Epidermal Growth Factor Receptor (EGFR) antibody drug conjugates (ADCs) which inhibit Bcl-xL, including compositions and methods using such ADCs, and methods for making such ADCs.

公开(公告)号：US20200255508A1

公开(公告)日：2020-08-13

申请号：US16576078

申请日：2019-09-19

Applicant: AbbVie Inc.

Inventor： Lorenzo Benatuil ,  Erwin R. Boghaert ,  Jijie Gu ,  Maria Harris ,  Jonathan A. Hickson ,  Chung-Ming Hsieh ,  Yuliya Kutskova ,  Yingchun Li ,  Zhihong Liu ,  Susan Morgan-Lappe

IPC: C07K16/22 ,  C07K7/08 ,  C07K7/06 ,  A61K45/06 ,  A61K39/395 ,  C07K16/18 ,  C07K14/47

Abstract: Improved DLL4 binding proteins are described, including antibodies, CDR-grafted antibodies, human antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis, and/or other angiogenesis-dependent diseases such as ocular neovascularization, or angiogenesis-independent diseases characterized by aberrant DLL4 expression or activity such as autoimmune disorders including multiple sclerosis.

公开(公告)号：US20200246460A1

公开(公告)日：2020-08-06

申请号：US16563507

申请日：2019-09-06

Applicant: AbbVie Inc.

Inventor： Scott L. Ackler ,  Nathan B. Bennett ,  Erwin R. Boghaert ,  Steve C. Cullen ,  George Doherty ,  Robin R. Frey ,  Anthony R. Haight ,  Andrew S. Judd ,  Aaron R. Kunzer ,  Violeta L. Marin ,  Xiaoqiang Shen ,  Xiaohong Song ,  Andrew J. Souers ,  Gerard M. Sullivan ,  Zhi-Fu Tao ,  Xilu Wang ,  Dennie S. Welch ,  Michael D. Wendt

IPC: A61K45/06 ,  A61K31/4725 ,  A61K31/4985 ,  A61K31/498 ,  A61K47/68 ,  A61K31/538 ,  A61K31/4709 ,  C07D417/14 ,  C07D487/04 ,  C07D513/04

Abstract: The present disclosure concerns Bcl-xL inhibitors having low cell permeability, antibody drug conjugates (ADCs) comprising the inhibitors, synthons useful for synthesizing the ADCs, compositions comprising the inhibitors or ADCs, and various methods of using the inhibitors and ADCs.

公开(公告)号：US20190142941A1

公开(公告)日：2019-05-16

申请号：US16240544

申请日：2019-01-04

Applicant: AbbVie Inc.

Inventor： Scott L. Ackler ,  Nathan B. Bennett ,  Erwin R. Boghaert ,  Steve C. Cullen ,  George Doherty ,  Robin R. Frey ,  Anthony R. Haight ,  Andrew S. Judd ,  Aaron R. Kunzer ,  Violeta L. Marin ,  Xiaoqiang Shen ,  Xiaohong Song ,  Andrew J. Souers ,  Gerard M. Sullivan ,  Zhi-Fu Tao ,  Xilu Wang ,  Dennie S. Welch ,  Michael D. Wendt

IPC: A61K45/06 ,  A61K47/68 ,  C07D513/04 ,  C07D487/04 ,  A61K31/538 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/498 ,  A61K31/4985 ,  C07D417/14

Abstract: The present disclosure concerns Bcl-xL inhibitors having low cell permeability, antibody drug conjugates (ADCs) comprising the inhibitors, synthons useful for synthesizing the ADCs, compositions comprising the inhibitors or ADCs, and various methods of using the inhibitors and ADCs.

公开(公告)号：US20160339117A1

公开(公告)日：2016-11-24

申请号：US14963506

申请日：2015-12-09

Applicant: AbbVie Inc.

Inventor： Scott L. Ackler ,  Nathan B. Bennett ,  Erwin R. Boghaert ,  Steve C. Cullen ,  George Doherty ,  Robin R. Frey ,  Anthony R. Haight ,  Andrew S. Judd ,  Aaron R. Kunzer ,  Violeta L. Marin ,  Xiaoqiang Shen ,  Xiaohong Song ,  Andrew J. Souers ,  Gerard M. Sullivan ,  Zhi-Fu Tao ,  Xilu Wang ,  Dennie S. Welch ,  Michael D. Wendt

IPC: A61K47/48 ,  C07D417/14 ,  A61K31/4725 ,  C07D487/04 ,  A61K31/538 ,  A61K31/498 ,  A61K31/4709 ,  A61K31/4985 ,  A61K45/06 ,  C07D513/04

CPC classification number: A61K45/06 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/498 ,  A61K31/4985 ,  A61K31/538 ,  A61K47/6803 ,  A61K47/6849 ,  A61K47/6851 ,  A61K47/6883 ,  A61K47/6889 ,  C07D417/14 ,  C07D487/04 ,  C07D513/04

Abstract: The present disclosure concerns Bcl-xL inhibitors having low cell permeability, antibody drug conjugates (ADCs) comprising the inhibitors, synthons useful for synthesizing the ADCs, compositions comprising the inhibitors or ADCs, and various methods of using the inhibitors and ADCs.

Abstract translation: 本公开涉及具有低细胞通透性的Bcl-xL抑制剂，包含抑制剂的抗体药物偶联物（ADC），可用于合成ADC的合成物，包含抑制剂或ADC的组合物，以及使用抑制剂和ADC的各种方法。

公开(公告)号：US20230077680A1

公开(公告)日：2023-03-16

申请号：US17447362

申请日：2021-09-10

Applicant: AbbVie Inc.

Inventor： Erwin R. Boghaert ,  Milan Bruncko ,  Andrew S. Judd ,  Andrew C. Phillips ,  Andrew J. Souers

IPC: A61K47/68 ,  A61P35/00 ,  C07K16/28

Abstract: The invention relates to anti-Epidermal Growth Factor Receptor (EGFR) antibody drug conjugates (ADCs) which inhibit Bcl-xL, including compositions and methods of using said ADCs.

公开(公告)号：US20200246323A1

公开(公告)日：2020-08-06

申请号：US16412729

申请日：2019-05-15

Applicant: AbbVie Inc.

Inventor： Scott L. Ackler ,  Erwin R. Boghaert ,  Milan Bruncko ,  George Doherty ,  Andrew S. Judd ,  Aaron R. Kunzer ,  Violeta L. Marin ,  Xiaohong Song ,  Andrew J. Souers ,  Gerard M. Sullivan ,  Zhi-fu Tao ,  Xilu Wang ,  Dennle S. Welch

IPC: A61K31/4545 ,  A61K47/68

Abstract: Small molecule Bcl-xL inhibitors and Antibody Drug Conjugates (ADCs) comprising small molecule Bcl-xL inhibitors are disclosed herein. The Bcl-xL inhibitors and ADCs of the disclosure are useful for, among other things, inhibiting anti-apoptotic Bcl-xL proteins as a therapeutic approach towards the treatment of diseases that involve a dysregulated apoptosis pathway.

公开(公告)号：US20200239553A1

公开(公告)日：2020-07-30

申请号：US16675784

申请日：2019-11-06

Applicant: AbbVie Inc.

Inventor： Scott L. Ackler ,  Nathan B. Bennett ,  Erwin R. Boghaert ,  Steve C. Cullen ,  George Doherty ,  Robin R. Frey ,  Anthony R. Haight ,  Andrew S. Judd ,  Aaron R. Kunzer ,  Xiaoqiang Shen ,  Xiaohong Song ,  Andrew J. Souers ,  Gerard M. Sullivan ,  Zhi-Fu Tao ,  Xilu Wang ,  Dennie S. Welch ,  Michael D. Wendt

IPC: C07K16/18 ,  C07D417/14 ,  C07D487/04 ,  C07D513/04 ,  A61K47/68

Abstract: Small molecule Bcl-xL inhibitors and Antibody Drug Conjugates (ADCs) comprising small molecule Bcl-xL inhibitors are disclosed herein. The Bcl-xL inhibitors and ADCs of the disclosure are useful for, among other things, inhibiting anti-apoptotic Bcl-xL proteins as a therapeutic approach towards the treatment of diseases that involve a dysregulated apoptosis pathway.

公开(公告)号：US20190153108A1

公开(公告)日：2019-05-23

申请号：US16308575

申请日：2017-06-07

Applicant: AbbVie Inc.

Inventor： Erwin R. Boghaert ,  Milan Bruncko ,  Andrew S. Judd ,  Andrew C. Phillips ,  Andrew J. Souers

IPC: C07K16/28 ,  A61P35/00 ,  A61K47/68 ,  A61K47/65 ,  A61K31/5377

Abstract: The invention relates to anti-Epidermal Growth Factor Receptor (EGFR) antibody drug conjugates (ADCs) which inhibit Bcl-xL, including compositions and methods of using said ADCs.

公开(公告)号：US20190153107A1

公开(公告)日：2019-05-23

申请号：US16308557

申请日：2017-06-07

Applicant: AbbVie Inc.

Inventor： Erwin R. Boghaert ,  Milan Bruncko ,  George Doherty ,  Robin R. Frey ,  Andrew S. Judd ,  Andrew C. Phillips ,  Xiaohong Song ,  Andrew J. Souers ,  Gerard M. Sullivan ,  Zhi-Fu Tao

IPC: C07K16/28 ,  A61P35/00 ,  A61K47/68 ,  A61K47/65

Abstract: The invention relates to anti-Epidermal Growth Factor Receptor (EGFR) antibody drug conjugates (ADCs) which inhibit Bcl-xL, including compositions and methods of using said ADCs.